BioSpace News Archive

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the appointment of Mark Foley as President and CEO, replacing Dan Browne, who has stepped down due to a misjudgment in handling an employee matter.

Patients newly diagnosed with pulmonary arterial hypertension (PAH) treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile, according to Olivier Sitbon, MD, PhD, from Université Paris–Sud, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.